CG Oncology (CGON) Competitors $27.90 -0.77 (-2.69%) (As of 01:52 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CGON vs. RVMD, LNTH, NUVL, BPMC, LEGN, ELAN, CYTK, TGTX, VKTX, and BBIOShould you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. CG Oncology vs. Revolution Medicines Lantheus Nuvalent Blueprint Medicines Legend Biotech Elanco Animal Health Cytokinetics TG Therapeutics Viking Therapeutics BridgeBio Pharma CG Oncology (NASDAQ:CGON) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do institutionals & insiders hold more shares of CGON or RVMD? 26.6% of CG Oncology shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 8.0% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in CGON or RVMD? Revolution Medicines received 71 more outperform votes than CG Oncology when rated by MarketBeat users. However, 90.48% of users gave CG Oncology an outperform vote while only 75.63% of users gave Revolution Medicines an outperform vote. CompanyUnderperformOutperformCG OncologyOutperform Votes1990.48% Underperform Votes29.52%Revolution MedicinesOutperform Votes9075.63% Underperform Votes2924.37% Is CGON or RVMD more profitable? Revolution Medicines has a net margin of 0.00% compared to CG Oncology's net margin of -10,642.98%. CG Oncology's return on equity of -18.97% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-10,642.98% -18.97% -15.36% Revolution Medicines N/A -33.67%-30.08% Does the media favor CGON or RVMD? In the previous week, CG Oncology had 1 more articles in the media than Revolution Medicines. MarketBeat recorded 9 mentions for CG Oncology and 8 mentions for Revolution Medicines. CG Oncology's average media sentiment score of 0.63 beat Revolution Medicines' score of 0.59 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, CGON or RVMD? CG Oncology has higher earnings, but lower revenue than Revolution Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$684K3,087.10-$48.61MN/AN/ARevolution Medicines$742K9,945.78-$436.37M-$3.59-12.22 Do analysts recommend CGON or RVMD? CG Oncology presently has a consensus price target of $63.88, indicating a potential upside of 130.01%. Revolution Medicines has a consensus price target of $65.82, indicating a potential upside of 50.03%. Given CG Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe CG Oncology is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 SummaryCG Oncology beats Revolution Medicines on 8 of the 15 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGON vs. The Competition Export to ExcelMetricCG OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$2.92B$5.16B$9.10BDividend YieldN/A1.91%5.12%4.26%P/E RatioN/A46.1187.5117.12Price / Sales3,087.10407.151,136.45119.65Price / CashN/A174.7643.2337.85Price / Book-14.313.874.784.77Net Income-$48.61M-$42.00M$120.55M$225.50M7 Day Performance-4.93%-2.89%-1.64%-1.29%1 Month Performance-17.03%1.36%14.04%0.45%1 Year PerformanceN/A16.74%28.88%15.38% CG Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGONCG Oncology1.9349 of 5 stars$27.90-2.7%$63.88+128.9%N/A$2.12B$684,000.000.0061Positive NewsRVMDRevolution Medicines4.4814 of 5 stars$44.75-0.6%$63.67+42.3%+61.5%$7.53B$11.58M-12.54443LNTHLantheus4.3778 of 5 stars$93.48+0.5%$130.00+39.1%+49.8%$6.50B$1.50B15.42834NUVLNuvalent2.1969 of 5 stars$87.42+0.6%$112.60+28.8%+15.2%$6.21BN/A-25.0340Positive NewsBPMCBlueprint Medicines2.5341 of 5 stars$95.39+2.4%$122.11+28.0%+1.5%$6.06B$434.42M-45.28640Insider TradeLEGNLegend Biotech1.55 of 5 stars$33.00-6.0%$81.54+147.1%-43.0%$6.03B$520.18M-36.971,800ELANElanco Animal Health3.6565 of 5 stars$12.15+0.4%$16.75+37.9%-20.7%$6.01B$4.45B30.389,300CYTKCytokinetics4.1349 of 5 stars$49.25+1.2%$83.93+70.4%+9.6%$5.81B$3.22M-9.04250Analyst ForecastTGTXTG Therapeutics3.8858 of 5 stars$34.40+7.4%$40.67+18.2%+89.4%$5.35B$233.66M-320.17290Analyst DowngradePositive NewsVKTXViking Therapeutics4.299 of 5 stars$47.43+0.9%$106.75+125.1%+122.4%$5.29BN/A-51.5620BBIOBridgeBio Pharma4.6395 of 5 stars$27.84+1.3%$47.69+71.3%-35.5%$5.26B$217.77M-11.63400Positive News Related Companies and Tools Related Companies Revolution Medicines Competitors Lantheus Competitors Nuvalent Competitors Blueprint Medicines Competitors Legend Biotech Competitors Elanco Animal Health Competitors Cytokinetics Competitors TG Therapeutics Competitors Viking Therapeutics Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGON) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
